Central pontine myelinolysis prevention

	Central pontine myelinolysis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Central pontine myelinolysis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Central pontine myelinolysis prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Central pontine myelinolysis prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Central pontine myelinolysis prevention
CDC on Central pontine myelinolysis prevention
Central pontine myelinolysis prevention in the news
Blogs on Central pontine myelinolysis prevention
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Central pontine myelinolysis prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Gradual, controlled treatment of low sodium levels may reduce the risk of nerve damage in the pons.

Being aware of how some medications can change sodium levels can prevent these levels from changing too quickly.